APA (7th ed.) Citation

O, Z., V, K., MK, R., I, M., A, R., R, M., . . . TM, W. (2025). Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Cancer research communications, 5(6), 939. https://doi.org/10.1158/2767-9764.CRC-25-0192

Chicago Style (17th ed.) Citation

O, Zamulko, et al. "Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma." Cancer Research Communications 5, no. 6 (2025): 939. https://doi.org/10.1158/2767-9764.CRC-25-0192.

MLA (9th ed.) Citation

O, Zamulko, et al. "Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma." Cancer Research Communications, vol. 5, no. 6, 2025, p. 939, https://doi.org/10.1158/2767-9764.CRC-25-0192.